Strides Pharma Science Second Quarter 2025 Earnings: EPS: ₹10.14 (vs ₹14.54 loss in 2Q 2024)

Simply Wall St · 10/26 02:08

Strides Pharma Science (NSE:STAR) Second Quarter 2025 Results

Key Financial Results

  • Revenue: ₹12.0b (up 20% from 2Q 2024).
  • Net income: ₹932.3m (up from ₹1.31b loss in 2Q 2024).
  • Profit margin: 7.8% (up from net loss in 2Q 2024). The move to profitability was primarily driven by higher revenue.
  • EPS: ₹10.14 (up from ₹14.54 loss in 2Q 2024).
earnings-and-revenue-growth
NSEI:STAR Earnings and Revenue Growth October 26th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Strides Pharma Science Earnings Insights

Looking ahead, revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in India.

Performance of the Indian Pharmaceuticals industry.

The company's shares are down 7.4% from a week ago.

Risk Analysis

Before you take the next step you should know about the 1 warning sign for Strides Pharma Science that we have uncovered.